Misplaced Pages

Ruboxistaurin

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Ruboxistaurin
Ball-and-stick model of the ruboxistaurin molecule
Clinical data
ATC code
  • none
Legal status
Legal status
  • US: Not FDA approved
Identifiers
IUPAC name
  • (9S)-9--6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzopyrrolooxadiazacyclohexadecine-18,20-dione
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H28N4O3
Molar mass468.557 g·mol
3D model (JSmol)
SMILES
  • CN(C1()CCN2C=C(C(C(O)=NC3=O)=C3C(C4=CC=CC=C45)=CN5CCO1)C6=CC=CC=C62)C
InChI
  • InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1
  • Key:ZCBUQCWBWNUWSU-SFHVURJKSA-N
  (what is this?)  (verify)

Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.

In February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an approvable letter from the US FDA for ruboxistaurin, with a request for an additional clinical trial, which would take 5 years to complete. Lilly has not made any further request for approval and ruboxistaurin is not approved by the FDA for any medical use.

Mechanism of action

Ruboxistaurin is an inhibitor of protein kinase C-beta.

References

  1. "Drugs.com, Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant". Retrieved 2008-02-15.
  2. "Drugs.com, Lilly Announces FDA Requirement of Additional Clinical Trial Before Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy". Retrieved 2008-02-15.
  3. "Arxxant Approval Status". drugs.com.
  4. Clarke M, Dodson PM (December 2007). "PKC inhibition and diabetic microvascular complications". Best Pract Res Clin Endocrinol Metab. 21 (4): 573–86. doi:10.1016/j.beem.2007.09.007. PMID 18054736.

External links


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories:
Ruboxistaurin Add topic